Role of altered GUT immune response in lewy body disease
Active Cooperative Agreement Awarded Last action
- Award ID
- U01DK140939
- Recipient
-
The Leland Stanford Junior University UEI HJD6G4D6TJY5
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,951,736
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 44% complete
- Place of performance
- Palo Alto, CA 94304, USA
Award details come from USAspending.gov.
Description
- Abstract
- Lewy body diseases (LBD), which include parkinson's disease (PD) and dementia with lewy bodies (DLB), represents a spectrum of progressive, debilitating neurological disorders for which there is no cure. Emerging evidence indicates that for some individuals with LBD and those with prodromal LBD (plbd), including those with isolated REM sleep behavior disorder (irbd), peripheral organs are involved including the GUT. Furthermore, peripheral insults including alterations to the GUT microbiota, immune dysregulation, and toxin exposure have been implicated in disease pathogenesis. However, few studies have provided comprehensive characterization of pathologic, immunologic, microbiologic and physiologic parameters in patients with PD or irbd thereby precluding definitive conclusions about the role peripheral organs have in pathobiology and disease signatures. The proposed multidisciplinary study will integrate novel technologies and concepts exploring the interplay between the GUT microbiota and the immune system in the pathogenesis of LBD. We have found that a population of GUT macrophages (MΦS) residing in the enteric nervous system (ENS), an autonomous branch of the peripheral nervous system that spans the gastrointestinal (GI) tract, shares genetic and functional characteristics with microglia, the predominant brain MΦ population critical to both pathogenesis and prevention of neurodegenerative disease. We identified clearance of α-synuclein (α-SYN) aggregates, the pathologic hallmark of LBD, as a homeostatic function of these MΦS. We propose a novel paradigm whereby the GUT microbiome influences neurodegenerative disease through immune mechanisms. We hypothesize that altered GUT neuro-immune interactions, mediated by microbial derived factors, promotes LBD progression. We will test this hypothesis through the following aims: aim 1 will use a multi-modal approach to characterized peripheral involvement in PD, irbd and healthy controls. Our analysis will include use of (i) a novel wearable HR-EGG-EEG device to interrogate GUT-brain function, (II) seed amplification assay on biopsy tissue to investigate enteric lewy pathology, (III) fecal analysis to evaluate microbiota structure/function, and (IV) characterization of immune response with flow cytometry, nanostring analysis, and immunoassays on colon biopsies and paired serum. Aim 2 will assess whether the microbiota promotes LBD by GUT immune mechanisms. We will directly test stool collected in aim 1 on mice using fecal microbiota transplants and evaluate effects on GUT immune phenotype/function. We will utilize an α- SYN GUT injection model to explore how microbiota modulation affects PD progression. Successful completion of the proposed studies will help understand critical pathophysiological pathways involved in early-stage PD and inform novel strategies to prevent, risk stratify, and treat those at risk for LBD.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $200,000 | |
| Amendment | $644,470 | |
| Amendment | $644,470 | |
| Amendment | $215,000 | |
| Amendment | $658,194 | |
| Amendment | $658,194 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $465,704 | |
| Original award | $465,704 |
Show all 11
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Palo Alto Veterans Institute For Research | $209,052 | |
| Palo Alto Veterans Institute For Research | $94,872 | |
| Palo Alto Veterans Institute For Research | $119,453 |
Quick answers
Who received award U01DK140939?
U01DK140939 was awarded to The Leland Stanford Junior University by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 1, 2024.
How much is award U01DK140939 worth?
$3,951,736 has been obligated on U01DK140939.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award